American Pharmaceutical Partners, Inc. Announces 2002 Second Quarter Financial Results Conference Call; Thursday, July 25, 2002, at 8:30 a.m. PT, 11:30 a.m. ET.Business Editors American Pharmaceutical Partners, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : APPX APPX Appendix APPX Application eXcellence (4GL software development tool) ), said that on Thursday, July 25, 2002, the company will release its financial results for its 2002 second quarter. The company also said that Patrick Soon-Shiong, M.D., the company's Chairman, President and Chief Executive Officer, and Derek Brown, Chief Financial Officer, will host an investor conference call that same day at 8:30 a.m., PDT PDT abbr. Pacific Daylight Time PDT Pacific Daylight Time PDT n abbr (US) (= Pacific Daylight Time) → hora de verano del Pacífico PDT (11:30 a.m. EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT ) to review the company's financial results and operations. This conference call will be available to interested parties through a live audio Internet broadcast at www.appdrugs.com and www.companyboardroom.com. The call will be archived and accessible at both sites beginning at 10:30 a.m. PDT, Thursday, July 25, 2002 through 10:30 a.m. PDT, Thursday, August 8, 2002. About American Pharmaceutical Partners, Inc. American Pharmaceutical Partners, Inc. (APP) is a specialty drug company that develops, manufactures and markets injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. pharmaceutical products, focusing on the oncology, anti-infective and critical care markets. The company is one of the largest producers of injectable pharmaceuticals, with more than 100 generic products in more than 300 dosages and formulations. Additionally, APP has acquired the exclusive North American North American named after North America. North American blastomycosis see North American blastomycosis. North American cattle tick see boophilusannulatus. rights to manufacture and market a proprietary injectable oncology product, currently in advanced clinical trials and being studied in a variety of cancers. For more information, visit APP's website at www.appdrugs.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion